Smart Measurement of Circulating Tumor DNA
Recruiting · NCT06989814 · Interventional (participants receive a specific treatment) · Lead sponsor: Erasmus Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
Blood Product
What this trial is about
The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages. Participants will be asked to take an extra blood test, which will be analyzed further in the lab.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- suspect) Lynch Syndrome carriers who:
- Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor;
- Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet;
- Have granted informed consent to participate in this study.
Exclusion criteria
- suspect) Lynch Syndrome carriers who:
- Are unwilling to undergo extra blood sampling;
- Are under the age of 18;
- Have no newly diagnosed tumors at time of inclusion;
- Have been treated for their tumor at time of inclusion;
- Are not able to read or understand Dutch language or are mentally not capable.
Where it is running
2 locations listed.
- Leiden University Medical Center - Leiden, South Holland, Netherlands
- Erasmus MC - Rotterdam, South Holland, Netherlands